Dr. Bradley Welling, Dr. Bob Carter | kyorin university school of medicine

Gene Therapy for NF2
iPSC derived Dopamine Progenitor Therapy for Parkinson’s Disease

November 07, 2023

Gene therapy for NF2, iPSC derived Dopamine Progenitor Therapy for Parkinson’s Disease Poster

I. Speaker: Dr. Bradley Welling

Walter Augustus Lecompte Professor of Otolaryngology-Head and Neck Surgery Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital, Harvard Medical School, Boston, USA

II. Speaker: Dr. Bob Carter

William and Elizabeth Sweet Professor and Chief, Department of Neurosurgery Massachusetts General Hospital, Harvard Medical School, Boston, USA

Gene therapy for NF2, iPSC derived Dopamine Progenitor Therapy for Parkinson’s Disease image3

Speaker: Professor Bradley Welling

Speaker: Professor Bob Carter

Gene therapy for NF2, iPSC derived Dopamine Progenitor Therapy for Parkinson’s Disease image4